Released Aug 8, 2023, after the close
10-Q filed Aug 8, 2023, 39 days after period end · 0000950170-23-039884
Q2 2023 · 10-Q
Revenue$187.02M$187.02M +58.4% vs Q2 2022+6.7% vs Q1 2023
Net Income-$39.43M-$39.43M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$1.07-$1.07 N/M vs Q2 2022N/M vs Q1 2023
Gross Profit$119,551,000+38.3%
Operating Income-$36,632,000N/M
Operating Cash Flowderived-$5,516,000N/M
Free Cash Flowderived-$17,867,000N/M
Margins · derived
Gross margin63.9%−9.3 pt vs Q2 2022
Operating margin-19.6%−25.2 pt vs Q2 2022
Net margin-21.1%−23.2 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $187.02M | $118.07M | $121.39M | $73.14M |
| Net Income | -$39.43M | $2.49M | $2.42M | -$18.42M |
| EPS Diluted | -$1.07 | $0.12 | $0.12 | -$0.96 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR